[go: up one dir, main page]

MX2023013062A - Monoterapia con inhibidores de shp2 y usos de la misma. - Google Patents

Monoterapia con inhibidores de shp2 y usos de la misma.

Info

Publication number
MX2023013062A
MX2023013062A MX2023013062A MX2023013062A MX2023013062A MX 2023013062 A MX2023013062 A MX 2023013062A MX 2023013062 A MX2023013062 A MX 2023013062A MX 2023013062 A MX2023013062 A MX 2023013062A MX 2023013062 A MX2023013062 A MX 2023013062A
Authority
MX
Mexico
Prior art keywords
recommended
generate
contact
tactic
orchestration
Prior art date
Application number
MX2023013062A
Other languages
English (en)
Inventor
Robert Goodenow
Mireille Gillings
Farbod Shojaei
Jill M Ricono
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of MX2023013062A publication Critical patent/MX2023013062A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

En el presente documento se proporcionan inhibidores de SHP2 para usarse en la reducción de tumores sólidos en un método de tratamiento del cáncer.
MX2023013062A 2021-05-05 2022-05-04 Monoterapia con inhibidores de shp2 y usos de la misma. MX2023013062A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184710P 2021-05-05 2021-05-05
US202263320991P 2022-03-17 2022-03-17
PCT/US2022/027703 WO2022235822A1 (en) 2021-05-05 2022-05-04 Shp2 inhibitor monotherapy and uses thereof

Publications (1)

Publication Number Publication Date
MX2023013062A true MX2023013062A (es) 2023-11-15

Family

ID=83932911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013062A MX2023013062A (es) 2021-05-05 2022-05-04 Monoterapia con inhibidores de shp2 y usos de la misma.

Country Status (8)

Country Link
US (1) US20220370458A1 (es)
EP (1) EP4333850A4 (es)
JP (1) JP2024516997A (es)
AU (1) AU2022271244A1 (es)
CA (1) CA3217097A1 (es)
IL (1) IL308234A (es)
MX (1) MX2023013062A (es)
WO (1) WO2022235822A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4334317A4 (en) * 2021-05-05 2025-03-05 Huyabio Int Llc COMBINATION THERAPIES INCLUDING SHP2 INHIBITORS AND EGFR TYROSINE KINASE INHIBITORS
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017274199B2 (en) * 2016-05-31 2021-09-23 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
CN109415360B (zh) * 2016-06-14 2021-11-02 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
KR20230156174A (ko) * 2016-07-12 2023-11-13 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
CN112368272B (zh) * 2018-03-21 2023-04-21 苏州浦合医药科技有限公司 Shp2抑制剂及其用途
WO2020165734A1 (en) * 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and ribociclib
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
WO2021061515A1 (en) * 2019-09-23 2021-04-01 Synblia Therapeutics, Inc. Shp2 inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2024516997A (ja) 2024-04-18
CA3217097A1 (en) 2022-11-10
EP4333850A4 (en) 2025-04-09
WO2022235822A1 (en) 2022-11-10
US20220370458A1 (en) 2022-11-24
IL308234A (en) 2024-01-01
AU2022271244A1 (en) 2023-12-07
EP4333850A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
MX2023013062A (es) Monoterapia con inhibidores de shp2 y usos de la misma.
EP4057279A3 (en) Natural assistant interaction
EP4435692A3 (en) Delayed responses by computational assistant
PH12019501623A1 (en) Blockchain-based data processing method and device
MX2020002510A (es) Metodos y dispositivos que realizan inversion de forma de onda completa cuadratica adaptable de wasserstein.
MX2021009175A (es) Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
MX2020010785A (es) Sistema fotovoltaico-electroquimico (pv-ec).
MX2022001584A (es) Tecnologias para presentacion de contenido.
MX388395B (es) Guardado y restauracion de estado de maquina entre multiples ejecuciones de una instruccion
WO2019204332A3 (en) Pak4 inhibitors and methods of use
MX2024010626A (es) Combinaciones de inhibidores de stat e inhibidores del punto de control inmunitario para el tratamiento y/o control del cancer.
FR2867401B1 (fr) Planeuse a entraxe variable
EP2100002A4 (en) CRUSH TREATMENT PROCESSES AND SYSTEMS FOR LIMESTONE DEPOSITS
Liu et al. Integrated Intelligent Scheduling Consideration and Function Realization of Domestic Trade Water Transport Planning in Baosteel Zhanjiang Iron & Steel Co., Ltd.
MX2024005401A (es) Concepto de reflexiones tempranas para auralizacion.
Rodrigues Furlani et al. Effect of laser surface hardening on a low carbon steel substrate wear and hardness
ZA202403483B (en) Concepts for auralization using early reflection patterns
Zhang et al. FastQSL: Quasi-separatrix Layers computation method
Dal Santo et al. Similarity metrics for late reverberation
Kochin et al. Nil-ductility transition temperature of ship plate and its connection with unit crack-propagation work
Chen et al. An Empirical Analysis on the Relationship between Corporate Social Responsibility and Enterprise Competitiveness
Li et al. LNG Forward Pricing Model Based on Stochastic Volatility
Pérez Zarazaga et al. Recovering implicit pitch contours from formants in whispered speech
Kutsenko Analytic solution of the wave equation in complex structures with defects, waveguides, sources